Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 5/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.32 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.32 |
| ▸ | BCKDK | O14874 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | DAO | P14920 | 2/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.30 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.30 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12895325 | 0.80 | HPGD (0.38) | HPGD | |
| SCHEMBL1267416 | 0.78 | ALDH1A1 (0.36) | MCL1LMNAHPGD | |
| SCHEMBL1266759 | 0.75 | BCKDK (0.36) | BCKDKLMNA | |
| SCHEMBL13871333 | 0.74 | OPRK1 (0.33) | — | |
| SCHEMBL1266124 | 0.73 | NOTUM (0.39) | MCL1RXFP1LMNAHPGD | |
| SCHEMBL2947085 | 0.70 | KMT2A (0.45) | LMNAHPGD | |
| SCHEMBL4277521 | 0.65 | MCL1 (0.67) | GPR35MCL1BCL2L1BCKDKRXFP1 | |
| SCHEMBL2950087 | 0.65 | UCHL1 (0.35) | GPR35MCL1BCKDKRXFP1DAO | |
| SCHEMBL3492612 | 0.64 | IKBKB (0.55) | GPR35RXFP1LMNAHPGD | |
| SCHEMBL346530 | 0.62 | MCL1 (0.62) | MCL1BCL2L1RXFP1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034495-A1 | Method of Modulating Stress-Activated Protein Kinase System | INTERMUNE, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-7521460-B2 | Thienopyridone derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2009-04-21 | — | — | US | disclosed |
| US-20070099894-A1 | e.g. 3-[(2,4-Difluorophenyl)amino]-2-{[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl}-7-phenylthieno[2,3-b]pyridin-6(7H)-one; autoimmune, neurodegenerative disorders, antiinflammatory agent; p38 MAP kinase inhibitor | CELLTECH R&D LIMITED (GB) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034495-A1 | Method of Modulating Stress-Activated Protein Kinase System | MAPKAPK2, MAP3K6, MAP3K2 | GPR35 3818/4885MCL1 884/4885BCL2L1 2170/4885 |
| US-20070099894-A1 | e.g. 3-[(2,4-Difluorophenyl)amino]-2-{[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl}-7-phenylthieno[2,3-b]pyridin-6(7H)-one; autoimmune, neurodegenerative disorders, antiinflammatory agent; p38 MAP kinase inhibitor | MAPK1, MAPKAPK2, MAPK6 | GPR35 2592/4885MCL1 2227/4885BCL2L1 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.